
|Articles|August 1, 2003
Radiotherapy for subfoveal CNV has early, but not durable benefits
Author(s)Cheryl Guttman
Fort Lauderdale, FL-High-dose (5 3 4-Gy fractions; 6 MeV) external-beam radiation therapy has only a modest and very short-lived benefit in the treatment of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), according to an interim analysis of data from the Age-Related Macular Degeneration Radiotherapy Trial (AMDRT).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
2
Collarettes common but largely stable in moderate-to-severe dry eye patients
3
Kiora Pharmaceuticals receives patent for additional and novel formulations of KIO-100 compounds
4
Prevent Blindness delegates first week of December as 5th annual geographic atrophy week
5

















































.png)


